You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Lipid Receptor GPR31 as a Target for Anti-Thrombotic and Stroke Therapy

    SBC: OASIS PHARMACEUTICALS, LLC            Topic: NHLBI

    Despite prevalent use of anti-platelet and anti-lipid therapies, stroke remains the third major cause of death and is the leading cause of adult disability in the US with an estimated cost in the range of $34 billion annually. Approximately 20% of the annual 795,000 stroke patients die within one year and 15-30% are permanently disabled. Antiplatelet therapy is mainly used for primary prevention o ...

    STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  2. Phase 1 Trial to Assess Safety and Immune Effects of Xenon Gas in Healthy Human Subjects

    SBC: General Biophysics LLC            Topic: NIA

    PHASE II APPLICATION(STTR Program PAS-22-197) “Phase 1 Trial to Assess Safety and Immune Effects of Xenon Gas in Healthy Human Subjects” ABSTRACTAlzheimer’s disease (AD) is one of the most prevalent neurodegenerative disorders. Emerging evidence shows that homeostatic dysregulation of the brain immune system, especially that orchestrated by microglia, plays a significant role in the onset an ...

    STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  3. Treatment of Inflammatory Complications of Respiratory Infection

    SBC: Respana Therapeutics, Inc            Topic: NIAID

    Abstract Respana Therapeutics is advancing a proprietary first-in-class therapeutic monoclonal antibody (mAb), RT- 002, for the treatment of debilitating and often lethal inflammatory complications associated with acute respiratory conditions. We have identified a lead candidate, RT-002, and an equally promising alternative. RT-002 targets the surfactant protein A receptor SP-R210, a host-mediated ...

    STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  4. Real-time Multimodal Diffuse Reflectance and Polarization Imaging Based Nerve Identification in Surgical Field of View

    SBC: YAYA SCIENTIFIC LLC            Topic: NIBIB

    PROJECT SUMMARY We propose to develop a novel non-contact, label-free multimodality imager that provides real-time intraoperative identification of nerves within the surgical field-of-view to facilitate the prevention of unintended nerve damage (termed iatrogenic nerve injury) during surgical procedures, as they are a major source of postsurgical complications, e.g., chronic pain. In the United St ...

    STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  5. SIRPant Technology for anti-Cancer Immunity

    SBC: SIRPANT IMMUNOTHERAPEUTICS INC            Topic: 102

    PROJECT SUMMARY Immune evasion is a hallmark of cancer. Various tumor immunotherapy treatments, such as immune checkpointblockade and cancer vaccination, have been developed to overcome cancer’s ability to avoid immune detectionand destruction; however, the result of these endeavors have not been satisfactory given a number of criticalbarriers. One of these barriers, and a prominent mechanism by ...

    STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  6. Molecular brush-conjugated antisense oligonucleotide as a pan-KRAS depletion agent

    SBC: PACDNA LLC            Topic: NCI

    Project Summary/Abstract Mutant forms of KRAS are a key driver in human tumors but remain partially refractory to therapeuticintervention. After over three decades of research, only a single inhibitor (sotorasib) targeting a singlemutation (KRASG12C) have reached market. The difficulty for developing small molecule KRAS inhibitorshas heightened the importance of alternative methods targeting the o ...

    STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  7. Optimizing Radiosynthetic Yield of [18F]FTT For Wide-Spread Distribution

    SBC: Trevarx Biomedical, Inc.            Topic: 102

    ABSTRACT: Poly (ADP-ribose) polymerase inhibitors (PARPi’s) have emerged as important therapeutic agents targeting a broadening class of gene mutations approved for treatment of breast, ovarian, prostate, and other cancers. Genomic assays of BRCA-related genes and tumor homologous repair deficiency are used as companion diagnostics for PARPi therapy but have imperfect predictive efficacy for PAR ...

    STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  8. Making Connections Thru Music: A Group Music Therapy-Based Intervention for Persons with Dementia

    SBC: HOPEFUL AGING LLC            Topic: R

    PROJECT SUMMARY/ABSTRACTHealthcare systems around the world, including within the United States, have long-established shortages of trained caregivers (WHO, 2016; Jones, Liu, Murfield, and Moyle, 2020). The American Health Care Association (2019) states that “the health care system has experienced a shortage of trained caregivers for critical roles for some time.” This scarcity directly impact ...

    STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  9. Fast and Radiation Hard Scintillators for High Dose Detection

    SBC: RADIATION MONITORING DEVICES, INC.            Topic: DTRA20B001

    The event of nuclear explosion generates harsh radiation conditions, evaluation of which is critical in protecting the military and civilian personnel from serious harm.  Due to these harsh conditions only very simple methods of radiation assessment are employed, such as measurement of equivalent dose.  Improvements to current instrumentation are sought that would provide energy resolved dose in ...

    STTR Phase II 2023 Department of DefenseDefense Threat Reduction Agency
  10. A novel PEDF peptide mimetic for diabetic retinopathy

    SBC: SKYRAN BIOLOGICS, INC.            Topic: NEI

    Abstract The overall goal of Skyran Biologics is to develop a potent topical therapeutic for diabetic retinopathy (DR), a leading cause of vision loss globally. Our research team identified Pigment Epithelium-Derived Factor (PEDF) and showed it is expressed in the eye and provides significant protection to the injured retina. Since its discovery, we identified a 44-mer N-terminus bioactive region ...

    STTR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government